A comprehensive understanding of the molecular landscape involving MALAT1, CD36, and lipogenic genes warrants further investigations and holds the potential to inform innovative therapeutic strategies aimed at mitigating the development and progression of NAFLD. This evidence concerns the gene CD36 and metabolic dysfunction-associated steatotic liver disease.